Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    Celebrate Oncology Nurse Leaders During Black History Month
    ONS Leadership
    Celebrate Oncology Nurse Leaders During Black History Month
    February 03, 2021
    Am I Too Shy to Lead?
    Nurse staffing
    Am I Too Shy to Lead?
    January 29, 2021
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Breast cancer

    Nursing Considerations for Breast Cancer Survivorship Care
    Breast cancer

    Nursing Considerations for Breast Cancer Survivorship Care

    More than 3.5 million people in the United States are living with a breast cancer diagnosis. Despite their large number, patients often report they do not receive appropriate follow-up care after completing treatment—and the situation is worsening, with pandemic-related delays in care affecting approximately half of breast cancer survivors.

    January 28, 2021
    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer
    Cancer treatments

    FDA Approves Margetuximab-cmkb for Metastatic HER2-Positive Breast Cancer

    On December 16, 2020, the U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb (Margenza™) in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who previously received two or more anti-HER2 regimens, at least one of which was for metastatic disease.

    December 18, 2020
    FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or Metastatic TNBC

    On November 13, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple negative breast cancer (TNBC) whose tumors express PD-L1 (combined positive score [CPS] ≥ 10) as determined by an FDA-approved test. FDA also approved the PD-L1 IHC 22C3 pharmDx as a companion diagnostic for selecting patients with TNBC for pembrolizumab.

    November 16, 2020
    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations
    Breast cancer

    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations

    In the United States, breast cancer is the most commonly diagnosed cancer in women. One in eight women will develop invasive disease in their lifetime with approximately 270,00 new cases diagnosed in the United States in 2019. Caucasian women have the highest incidence rate, whereas African American women are most likely to die from the disease. The five-year survival rate is 91%, with an estimated 3.8 million breast cancer survivors living in the United States.

    October 15, 2020
    FDA Rejects Atezolizumab in Combination With Paclitaxel as Treatment for Breast Cancer 
    U.S. Food and Drug Administration (FDA)

    FDA Rejects Atezolizumab in Combination With Paclitaxel as Treatment for Breast Cancer 

    On September 8, 2020, the U.S. Food and Drug Administration (FDA) announced it did not approve atezolizumab (Tecentriq®) in combination with paclitaxel for treatment of breast cancer after a clinical trial studying the use of atezolizumab and paclitaxel in patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer (mTNBC) showed the drug combination did not work to treat the disease.   

    September 09, 2020
    ACA Led to Higher Rates of Early Breast Cancer Diagnoses
    Research

    ACA Led to Higher Rates of Early Breast Cancer Diagnoses

    Thanks to expanded Medicaid coverage from the Affordable Care Act (ACA), women diagnosed with breast cancer—and in particular, African American women who are more likely to experience breast cancer disparities—are getting their cancers found at earlier stages, according to researchers. The study findings were reported in JAMA Surgery.

    August 19, 2020
    Insulin Resistance May Explain Racial Disparity in Breast Cancer
    Cancer research

    Insulin Resistance May Explain Racial Disparity in Breast Cancer

    Black women with breast cancer typically have a worse prognosis than white women, and the results of a new study suggest that insulin resistance may be a factor in the disparity. Findings from the study were reported in Breast Cancer Research.

    July 22, 2020
    Dietary Supplements May Affect Breast Cancer Chemo Outcomes
    Chemotherapy

    Dietary Supplements May Affect Breast Cancer Chemo Outcomes

    Antioxidant supplements are associated with increased disease recurrence and statistically nonsignificant increased risk of mortality in patients with breast cancer who were receiving cyclophosphamide, doxorubicin, and paclitaxel, according to findings from a study reported in the Journal of Clinical Oncology.

    May 13, 2020
    FDA Grants Accelerated Approval to Sacituzumab Govitecan-Hziy for Metastatic Triple-Negative Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Sacituzumab Govitecan-Hziy for Metastatic Triple-Negative Breast Cancer

    April 23, 2020
    FDA Approves First New Drug Under International Collaboration, a Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer 
    U.S. Food and Drug Administration (FDA)

    FDA Approves First New Drug Under International Collaboration, a Treatment Option for Patients With HER2-Positive Metastatic Breast Cancer 

    On April 17, 2020, as part of Project Orbis, the U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa™) in combination with chemotherapy (trastuzumab and capecitabine) for the treatment of adult patients with advanced forms of HER2-positive breast cancer that can’t be removed with surgery or have spread to other parts of the body, including the brain, and who have received one or more prior treatments. 

    April 20, 2020
    New Treatments Show Promise for Metastatic HER2-Positive Breast Cancer
    Breast cancer

    New Treatments Show Promise for Metastatic HER2-Positive Breast Cancer

    Two new drugs in clinical trials are extending survival for women with metastatic HER2-positive breast cancer that had progressed with previous treatment. One of the drugs was effective for brain metastasis, which is particularly difficult to treat. Results from both studies were reported in the New England Journal of Medicine. 

    April 15, 2020
    Genomic Classifier Predicts Breast Cancer Radiation Benefit, Recurrence Risk
    Breast cancer

    Genomic Classifier Predicts Breast Cancer Radiation Benefit, Recurrence Risk

    The Adjuvant Radiotherapy Intensification Classifier (ARTIC) predicts which women with early-stage breast cancer will benefit the most from radiotherapy, as well as their risk for locoregional recurrence after radiation, researchers reported in study findings published in the Journal of Clinical Oncology. 

    March 30, 2020
    Latinas’ Breast Cancer Genetic Disparities Require More Focused Counseling and Testing
    Breast cancer

    Latinas’ Breast Cancer Genetic Disparities Require More Focused Counseling and Testing

    Breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death in Latina women. Compared to all patients with breast cancer, Latinas are the second most common ethnic group to carry BRCA1 deleterious mutations, after Ashkenazi Jewish women. However, Latinas are less likely to receive genetic counseling education, referrals, and testing services and have the least awareness of genetic testing compared to non-Hispanic whites and other minority populations. Research indicates that despite their low awareness, Latinas have high interest in participating in genetic counseling and testing. 

    March 27, 2020
    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer

    On February 25, 2020, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlyn®) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

    February 26, 2020
    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up
    Treatments

    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up

    January 22, 2020
    Breast Cancer Is More Fatal in Men Than Women
    Breast cancer

    Breast Cancer Is More Fatal in Men Than Women

    Men have higher death rates than women across all stages of breast cancer, study findings reported in JAMA Oncology show. In the study, five-year overall survival after a breast cancer diagnosis was 77.6% for men and 86.4% for women.

    January 15, 2020
    Multigene Testing Is Cost Effective for All Women With Breast Cancer
    Genetics & genomics

    Multigene Testing Is Cost Effective for All Women With Breast Cancer

    According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.

    December 20, 2019
    Research Guides the Transition of PEP Resources to ONS Guidelines
    Research

    Research Guides the Transition of PEP Resources to ONS Guidelines

    Lymphedema is one of the most common treatment side effects in patients with breast cancer. Estimates suggest that approximately 40% of all breast cancer survivors are at risk to develop lymphedema at some point in their lives. But as far back as 1998 and even before, some healthcare experts were predicting that lymphedema would be eliminated as a side effect from breast cancer treatment. Twenty-one years later, it’s still prevalent among breast cancer survivors, requiring careful management recommendations from oncology nurses to help patients live with this chronic issue.

    December 10, 2019
    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer
    Breast cancer

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

    Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.

    December 04, 2019
    USPSTF Updates Recommendations on Breast Cancer Prevention
    Research

    USPSTF Updates Recommendations on Breast Cancer Prevention

    Certain groups of women who are at increased risk for carrying BRCA1 or BRCA2 genes should be assessed for the need for genetic testing, and women at increased risk for breast cancer and low risk of adverse events should be offered risk-reducing medications, the U.S. Preventive Services Task Force (USPSTF) recommended.

    November 06, 2019
    Getting the Right Treatment at the Right Time Reduces Inequities in Breast Cancer Survival
    Cancer health disparities

    Getting the Right Treatment at the Right Time Reduces Inequities in Breast Cancer Survival

    Although death rates from breast cancer have been falling, the trend has not been equal among all women. Looking at breast cancer survival on a population level can tell us how effective our public health and healthcare systems are at early diagnosis, delivery of evidence-based treatment, and management of follow-up care.

    October 08, 2019
    Pediatric Cancer Survivors Have Higher Mortality After Adult Breast Cancer Diagnosis
    Survivorship

    Pediatric Cancer Survivors Have Higher Mortality After Adult Breast Cancer Diagnosis

    Women who survived pediatric cancer but developed breast cancer as an adult are more than twice as likely to die prematurely, mostly from comorbid conditions, according to results of a study published in the Journal of Clinical Oncology.

    October 02, 2019
    Wasserman Schultz, Brooks Introduce EARLY Act for Breast Cancer Awareness
    Health Policy

    Wasserman Schultz, Brooks Introduce EARLY Act for Breast Cancer Awareness

    Health care is the top domestic policy issue for Americans, but with so many different ideas to make the healthcare system more accessible and affordable, the issue is becoming increasingly complex. Because of its far-reaching impact, health care is often a politically charged topic and little change has yet been seen on a legislative level.

    August 19, 2019
    Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer
    Treatments

    Oncology Drug Reference Sheet: Atezolizumab’s Indications for Breast and Lung Cancer

    The U.S. Food and Drug Administration (FDA) first approved atezolizumab (Tecentriq®) in 2016, but it received additional approvals when used in combination treatments for locally advanced or metastatic triple negative breast cancer (TNBC) and small cell lung cancer (SCLC) in March 2019.

    July 23, 2019
    Test Predicts Which Women Will Benefit From Chemo for Breast Cancer
    Breast cancer

    Test Predicts Which Women Will Benefit From Chemo for Breast Cancer

    A prediction test accurately identifies which women with estrogen receptor (ER)-positive, HER2-negative breast cancer will benefit from adjuvant chemotherapy, according to the results of a study published in Breast Cancer Research and Treatment. 
     

    July 03, 2019
    FDA Links Breast Implants to Increased ALCL Risk
    U.S. Food and Drug Administration (FDA)

    FDA Links Breast Implants to Increased ALCL Risk

    People with breast implants have a risk of developing breast implant-associated anaplastic large cell lymphoma (ALCL), the U.S. Food and Drug Administration (FDA) announced in April 2019. Typically the cancer is limited to the scar tissue and fluid near an implant, but some patients experience spread throughout the body. The risk increases with textured implants in particular.

    June 12, 2019
    FDA Approves Alpelisib for Metastatic Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Alpelisib for Metastatic Breast Cancer

    On May 24, 2019, the U.S. Food and Drug Administration (FDA) approved alpelisib (Piqray®) in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.

    May 27, 2019
    CDC’s Triple-Negative Breast Cancer Virtual Program Helps Patients Understand the Disease
    Health Policy

    CDC’s Triple-Negative Breast Cancer Virtual Program Helps Patients Understand the Disease

    Unlike other types of breast cancer, a triple-negative diagnosis doesn’t have any of the common receptors found in other breast cancers, presenting potential treatment challenges to patients and providers. To assist patients with triple-negative breast cancer, the Centers for Disease Control and Prevention (CDC) created a new virtual program, allowing patients to consult and ask questions to a virtual coach in the comfort of their own homes.

    May 18, 2019
    The Case of the Terrible Toxicities
    Adverse events

    The Case of the Terrible Toxicities

    After completing neoadjuvant chemotherapy for triple-negative invasive breast cancer, Madeline, age 32, had a bilateral mastectomy with reconstructive surgery. Final pathology showed residual disease in the breast and one lymph node, and her oncologist recommended adjuvant therapy with capecitabine (1,500 mg twice a day for 14 days, off for 7 days). Five weeks postoperatively, she started cycle 1. Eight days later, her husband called the cancer clinic reporting that over the past two days, his wife developed profound weakness, unremitting diarrhea despite using diphenoxylate and atropine as directed, and painful, red, swollen hands and feet. Her symptoms represented a drastic change from her usual routine and energy level.

    May 14, 2019
    FDA Approves Ado-Trastuzumab Emtansine for Early Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ado-Trastuzumab Emtansine for Early Breast Cancer

    On May 3, 2019, the U.S. Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kakcyla®) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

    May 06, 2019
    FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

    On March 8, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to atezolizumab in combination with paclitaxel protein-bound for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test.

    March 11, 2019
    FDA Approves Trastuzumab and Hyaluronidase-oysk Injection for Subcutaneous Use
    U.S. Food and Drug Administration (FDA)

    FDA Approves Trastuzumab and Hyaluronidase-oysk Injection for Subcutaneous Use

    On February 28, 2019, the U.S. Food and Drug Administration (FDA) approved a trastuzumab and hyaluronidase-oysk injection, for subcutaneous use (Herceptin Hylecta). The drug is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, for the treatment of HER2‑overexpressing breast cancer. 

    March 01, 2019
    BRCA Is Not the Only Common Mutation for Breast and Ovarian Cancer
    Research

    BRCA Is Not the Only Common Mutation for Breast and Ovarian Cancer

    Multigene testing for hereditary breast and ovarian cancer has increased the detection predisposition genes beyond BRCA1 and BRCA2, according to study findings presented at the San Antonio Breast Cancer Symposium on December 7, 2018. 

    January 02, 2019
    San Antonio Breast Cancer Symposium

    Comorbidities Negatively Impact Breast Cancer Survival

    Missouri has a high breast cancer mortality rate, as well as high rates of type 2 diabetes, cardiovascular disease (CVD), and hypertension, which present more often in individuals who are poor, those living in rural areas, African Americans, and older adults. Women with comorbidities at the time of breast cancer diagnosis may have a worse prognosis, so researchers assessed survival disparities among these patient populations. According to the findings presented at the San Antonio Breast Cancer Symposium on December 5, 2018, comorbidities can negatively impact overall breast cancer survival.

    December 14, 2018
    San Antonio Breast Cancer Symposium

    Glutathione Plays a Role in Treatment-Related CINV

    Chemotherapy-induced nausea and vomiting (CINV) can negatively affect nutritional intake, ability to work, and treatment adherence. Research suggests that younger age and female gender are the strongest predictors of CINV, but those may not be the only factors, particularly for delayed nausea, according to research findings presented at the San Antonio Breast Cancer Symposium on December 5, 2018.

    December 13, 2018
    San Antonio Breast Cancer Symposium

    Circulating Tumor Cells Predict Survival

    Circulating tumor cells (CTCs) are identified in 20%–25% of patients with nonmetastatic breast cancer, and recent research suggests that detection of CTCs at five-year follow-up may predict late recurrence for nonmetastatic, estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In a study presented at the San Antonio Breast Cancer Symposium on December 6, 2018, researchers from the University of Texas MD Anderson Cancer Center found that the presence of CTCs in patients with nonmetastatic breast cancer was associated with shortened relapse-free survival (RFS), regardless of the subtype.

    December 13, 2018
    San Antonio Breast Cancer Symposium

    Educational Workshop Improves Patient-Perceived Knowledge About Their Disease

    Patient education can improve interactions with their healthcare team and provide coping mechanisms for the psychosocial effects of metastatic breast cancer, according to study findings presented at the San Antonio Breast Cancer Symposium on December 8, 2018.

    December 12, 2018
    San Antonio Breast Cancer Symposium

    Tailored Education Improves Patient Satisfaction and Comprehension

    Throughout the course of treatment, patients with breast cancer receive a significant amounts of information from their healthcare team. Researchers at the University of Colorado School of Medicine assessed and revamped the educational materials from the facility’s Memorial Radiation Oncology Department to achieve a patient comprehension of key treatment-related concepts of 75%. They found that although some educational concepts remained unmemorable or improperly emphasized, overall trends in comprehension indicated that a patient-tailored approach led to better satisfaction and outcomes, according to the findings presented at the San Antonio Breast Cancer Symposium on December 8, 2018.

    December 11, 2018
    San Antonio Breast Cancer Symposium

    Trastuzumab Remains Standard HER2+ Breast Cancer Therapy Despite Cardiac Risks

    Trastuzumab can improve disease-free survival (DFS) and overall survival (OS) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Although some studies suggest that short-term treatment (less than one year) may reduce cardiac toxicity and cost without compromising outcomes, the results of a new study presented at the San Antonio Breast Cancer Symposium on December 8, 2018, disagree.

    December 10, 2018
    San Antonio Breast Cancer Symposium

    Study Identifies Novel Triplet Therapy for HR+/HER2+ Breast Cancer

    Researchers from the University of Colorado Denver Young Women Breast Cancer Translational Program in Aurora identified a potential triplet combination for the treatment of hormone receptor-positive (HR+) human epidermal growth factor receptor 2-positive (HER2+) breast cancer: HER2-targeted small molecule inhibitor tucatinib, CDK4/6 inhibitor palbociclib, and selective estrogen receptor blocker fulvestrant. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Highly Emetogenic Chemotherapy Still Contributes to Potentially Avoidable Adverse Events

    The Centers for Medicare and Medicaid Services (CMS) implemented an oncology outcome measure to assess the quality of care and determine outpatient hospital payment (OP-35: Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy). The measure assesses 30-day postchemotherapy rates of inpatient or emergency department (ED) events deemed “potentially avoidable” because of an association with any of the 10 CMS-defined toxicities: anemia, dehydration, diarrhea, fever, nausea, emesis, neutropenia, pain, pneumonia, or sepsis. Researchers sought to assess those events when linked to highly emetogenic chemotherapy (HEC) in patients treated with anthracycline plus cyclophosphamide (AC), carboplatin, or cisplatin. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Social Support May Play a Role in Treatment Adherence

    Many women discontinue adjuvant endocrine therapy (AET) because of adverse events (AEs), and only half remain adherent at five years. Researchers from the University of Southern California, Los Angeles, found that continued social support for those women may improve AET adherence. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Socioeconomic Factors Predict Survival in Nonmetastatic Breast Cancer

    Racial and regional disparities impact the incidence of, mortality from, and survival from breast cancer, but the role of other socioeconomic factors is unclear. Researchers from Fudan University in Shanghai, China, conducted a large study and found that marital status, insurance status, median household income, and residence also contribute to survival from nonmetastatic breast cancer. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Breast MRI Protocol Improves Patient Care

    Magnetic resonance imaging (MRI) can help diagnose breast cancer, but it is costly. Leadership at the University of Washington in Bellingham developed a protocol to improve the timeliness of care, moving the time of MRI prior to surgeon evaluation, and found that it led to enhanced patient care, eliminated delays in treatment, avoided unnecessary tests, shifted appropriate care to primary-care providers, and provided all necessary data prior to initial surgical consultation. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Patients Rank the Importance of PRO Measures Differently

    Patient-reported outcomes (PROs) can improve patient satisfaction and potentially impact survival. However, PRO data are not well-collected outside of the research setting. Researchers at the Yale School of Medicine in New Haven, CT, conducting qualitative study assessed the most personally relevant PROs in women with metastatic breast cancer and observed substantial variation in patient preferences. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Time to Treatment Discontinuation Shorter in Patients Who Receive First-Line Palbociclib

    Current treatment guidelines recommend sequential hormone therapy for patients with hormone receptor-positive (HR+) metastatic breast cancer who are not in visceral crisis and whose disease is not refractory to endocrine treatment. Second-line fulvestrant monotherapy is a treatment option for patients in whom disease progresses after first-line palbociclib. Researchers used real-world data to evaluate the time to treatment discontinuation (TTD) of second-line fulvestrant in patients with HR+ human epidermal growth factor receptor 2-negative (HER2–) metastatic breast cancer who did (n = 88) and did not (n = 100) receive first-line palbociclib and found it was shorter in patients who received palbociclib. They presented the findings at the San Antonio Breast Cancer Symposium on December 7, 2018.

    December 07, 2018
    San Antonio Breast Cancer Symposium

    Overall Survival From Breast Cancer Differs Based on Tumor Type and Location

    Triple-negative breast cancer tumors are thought to be more immunogenic than other breast cancer subtypes, such as luminal A/B or human epidermal growth factor receptor 2-positive (HER2+) tumors. Among all breast cancers, tumors appear more commonly in the upper outer quadrant. However, it is not clear whether expression of immune response genes vary with tumor location among the different subtypes. Researchers assessed gene expression associated with immune response pathways to identify potential treatment targets and presented the findings at the San Antonio Breast Cancer Symposium on December 6, 2018.

    December 06, 2018
    San Antonio Breast Cancer Symposium

    Tumor Heterogeneity May Affect Outcomes in Patients With DCIS

    Intratumor heterogeneity can lead to cancer progression, and tumors with the highest levels of heterogeneity may be more likely to progress. Researchers compared mutational loads from separate areas of pure ductal carcinoma in situ (DCIS) to genetic heterogeneity in DCIS lesions that coexist with invasive cancer and presented the findings at the San Antonio Breast Cancer Symposium on December 6, 2018.

    December 06, 2018
    San Antonio Breast Cancer Symposium

    On-Treatment Genetic Testing Improves Accuracy of Tumor Response Prediction

    Genetic testing during treatment can improve accuracy of response and outcome prediction compared to other prognostic tests, according to results from a study assessing on-treatment changes in gene expression in patients receiving chemotherapy. Researchers from Oikonomidou O Institute of Genetics and Molecular Medicine in Edinburgh, United Kingdom, presented the findings at the San Antonio Breast Cancer Symposium on December 6, 2018.

    December 06, 2018
    San Antonio Breast Cancer Symposium

    Study Identifies Factors Associated With Long-Term Survival in Metastatic Breast Cancer

    Few women with metastatic breast cancer live five years or longer, and predictors of long-term survival are not well understood. Researchers from the University of Pittsburgh Medical Center (UPMC) in Pennsylvania identified demographic- and disease-specific factors related to survival and presented their findings at the San Antonio Breast Cancer Symposium on December 6, 2018.

    December 06, 2018
    • Current page 1
    • Page 2
    • Page 3
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲